• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Novo Nordisk A/S Common Stock (NY:NVO)

    46.23 -0.95 (-2.00%)
    Streaming Delayed Price Updated: 1:51 PM EDT, Aug 12, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 5,721,576
    Open 45.87
    Bid (Size) 46.22 (100)
    Ask (Size) 46.23 (800)
    Prev. Close 47.17
    Today's Range 45.56 - 46.30
    52wk Range 35.12 - 64.16
    Shares Outstanding N/A
    Dividend Yield 5.52%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Hims & Hers’ Revenue Beat Came With a Profitability Problem ↗
    Hims & Hers topped Q2 revenue estimates and raised guidance, but missed EPS forecasts, posted a wider net loss, and faces an FTC lawsuit, leaving Wall Street cautious with a Hold rating. 
    Via MarketBeat
    Topics Earnings Lawsuit
    News headline image
    Novo Nordisk Stock: Buy or Sell? ↗
    Sales of weight loss treatments have been incredible for Novo Nordisk. 
    Via The Motley Fool

    Performance

    YTD
    -11.8%
    -11.8%
    1 Month
    -6.2%
    -6.2%
    3 Month
    -1.6%
    -1.6%
    6 Month
    -5.9%
    -5.9%
    1 Year
    -7.3%
    -7.3%

    More News

    Read More
    News headline image
    Better Buy: Eli Lilly vs. Novo Nordisk ↗
    Via The Motley Fool
    News headline image
    Why Eli Lilly Topped the Market Today ↗
    Via The Motley Fool
    News headline image
    Novo Nordisk A/S Q2 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    News headline image
    Eli Lilly's Timing of the FDA Filing of Its Next Weight-Loss Drug Is Now Official -- and Novo Nordisk Has a Problem ↗
    Via The Motley Fool
    News headline image
    Pfizer's Next Weight-Loss Weapon: How Berobenatide Stacks Up Against Novo Nordisk's Wegovy and Eli Lilly's Zepbound ↗
    Via The Motley Fool
    News headline image
    Why Is Everyone Talking About Novo Nordisk? ↗
    Via The Motley Fool
    News headline image
    The FTC Is Suing Hims & Hers Health—Here's Why Investors Shouldn't Panic ↗
    Via MarketBeat
    Topics Lawsuit
    News headline image
    Bearish Pressure Is Building Around These 3 Stocks ↗
    Via MarketBeat
    Topics Artificial Intelligence
    News headline image
    Novo Nordisk Shares Plunge After a Key Trial Fails. Should Investors Buy the Dip? ↗
    Via The Motley Fool
    News headline image
    Eli Lilly Stock Has Skyrocketed. Novo Nordisk Has Crashed. 1 Number Explains Why They're Not Even Close Anymore. ↗
    Via The Motley Fool
    News headline image
    3 Beaten-Down Stocks With GLP-1 Exposure to Buy and Hold ↗
    Via The Motley Fool
    News headline image
    Watch Out, Eli Lilly and Novo Nordisk: Amgen's Monthly Weight Loss Drug Has 6 Phase 3 Trials Running -- and It's Coming for Your Patients ↗
    Via The Motley Fool
    News headline image
    Where Will Novo Nordisk Stock Be in 3 Years? ↗
    Via The Motley Fool
    News headline image
    Why Is Novo Nordisk Suing Eli Lilly, and What Does it Mean for Investors? ↗
    Via The Motley Fool
    Topics Lawsuit
    News headline image
    2 Top Growth Stocks to Buy Right Now Without Any Hesitation ↗
    Via The Motley Fool
    News headline image
    3 Absurdly Cheap Dividend Stocks to Buy With $1,000 Right Now ↗
    Via The Motley Fool
    Topics Lawsuit
    News headline image
    "Deceptive Advertising!" Claims Novo Nordisk in Explosive New GLP-1 Lawsuit Against Eli Lilly. Here's What That Means for Both Stocks. ↗
    Via The Motley Fool
    Topics Lawsuit
    News headline image
    Novo Nordisk's Dividend Story Is Changing -- Here's What Investors Are Missing ↗
    Via The Motley Fool
    News headline image
    Next-Generation Diabetes Therapies Are Reshaping Healthcare and Creating MultiBillion-Dollar Revenue Opportunities
    Via FinancialNewsMedia
    News headline image
    Could Pfizer Ultimately Be the Biggest Winner in the $100 Billion Weight-Loss Market? ↗
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics Just Started Testing a Weight Loss Drug That Goes Beyond GLP-1 ↗
    Via The Motley Fool
    News headline image
    The Most Overlooked Reason Eli Lilly Stock Keeps Surging -- and It Has Nothing to Do With Weight Loss ↗
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Wegovy Pill Just Changed the GLP-1 Market. Here's Why Eli Lilly Stock Could Still Win ↗
    Via The Motley Fool

    Frequently Asked Questions

    Is Novo Nordisk A/S Common Stock publicly traded?
    Yes, Novo Nordisk A/S Common Stock is publicly traded.
    What exchange does Novo Nordisk A/S Common Stock trade on?
    Novo Nordisk A/S Common Stock trades on the New York Stock Exchange
    What is the ticker symbol for Novo Nordisk A/S Common Stock?
    The ticker symbol for Novo Nordisk A/S Common Stock is NVO on the New York Stock Exchange
    What is the current price of Novo Nordisk A/S Common Stock?
    The current price of Novo Nordisk A/S Common Stock is 46.23
    When was Novo Nordisk A/S Common Stock last traded?
    The last trade of Novo Nordisk A/S Common Stock was at 08/12/26 01:51 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.